How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

被引：0
|
作者：
Zheng, Lucy [1 ]
Zheng, X. Long [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd,Delp 5016, Kansas City, KS 66160 USA
来源：
ANNALS OF BLOOD | 2023年 / 8卷
关键词：
PLASMA-EXCHANGE; REFRACTORINESS; MORTALITY; ADAMTS13;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
    Cilla, Nicolas
    Dallemagne, Julie
    Vanhove, Marie
    Stordeur, Patrick
    Motte, Serge
    De Wilde, Virginie
    JOURNAL OF HEMATOLOGY, 2020, 9 (03) : 84 - 88
  • [42] Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
    Kuehne, Lucas
    Kaufeld, Jessica
    Voelker, Linus A.
    Wendt, Ralph
    Schoenermarck, Ulf
    Haegele, Holger
    Osterholt, Thomas
    Eichenauer, Dennis A.
    Bieringer, Markus
    Bergwelt-Baildon, Anke
    Fischereder, Michael
    Buxhofer-Ausch, Veronika
    Menne, Jan
    Brinkkoetter, Paul T.
    Knoebl, Paul
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (04) : 951 - 960
  • [43] Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons
    Segui, Ines Gomez
    Mingot Castellano, Maria Eva
    Izquierdo, Cristina Pascual
    de la Rubia, Javier
    EXPERT REVIEW OF HEMATOLOGY, 2024, : 9 - 25
  • [44] Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura
    Galstyan, Gennadiy M.
    Klebanova, Elizaveta
    Mamleeva, Svetlana
    Fidarova, Zalina
    Drokov, Michail
    Bessmertniy, Dmitriy
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2024,
  • [45] CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): TECHNOLOGY QUALIFICATION IN COLOMBIA
    Soto, J.
    Gomez, L. M.
    Lasalvia, P.
    Castellanos, C.
    Casallas, C.
    Londono, S.
    VALUE IN HEALTH, 2023, 26 (06) : S274 - S274
  • [46] Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Kuehne, Lucas
    Eichenauer, Dennis A.
    Knoebl, Paul
    Voelker, Linus A.
    Kaufeld, Jessica
    Wendt, Ralph
    Haegele, Holger
    Osterholt, Thomas
    Bieringer, Marcus
    Buxhofer-Ausch, Veronika
    Menne, Jan
    Schoenermarck, Ulf
    Brinkkoetter, Paul
    BLOOD, 2021, 138
  • [47] Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
    Pramanik, Debolina
    Bhardwaj, Divyashish
    Karmani, Vikash K.
    Raval, Girindra G.
    Kutlar, Abdullah
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [48] HEALTHCARE COSTS AVOIDED IN THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA WITH CAPLACIZUMAB IN COLOMBIA
    Londono, S.
    Gil-Rojas, Y.
    Lasalvia, P.
    VALUE IN HEALTH, 2023, 26 (06) : S69 - S69
  • [49] Cost-Effectiveness of Caplacizumab in the Warranty Program in Immune Thrombotic Thrombocytopenic Purpura in the USA
    Sullivan, Sean D.
    Chaturvedi, Shruti
    Gautam, Preety
    Arnaud, Alix
    BLOOD, 2023, 142
  • [50] Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
    Palanques-Pastor, Tomas
    Megias-Vericat, Juan Eduardo
    Boso Ribelles, Virginia
    Gomez Segui, Ines
    Poveda Andres, Jose Luis
    ACTA HAEMATOLOGICA, 2022, 145 (01) : 72 - 76
12345